🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in France / NCT03077178
Active, not recruiting Not applicable

Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over

NCT03077178 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2017-11-30
Last updated
2026-01-30

Condition(s) studied

Soft Tissue Sarcoma Adult

Investigational drug(s) / intervention(s)

Geriatric assessment

Geriatric assessment: Geriatric assessment, questionnaire assessment

Study summary

In order to describe functional impact of surgery in elderly patients treated for lower-limb soft-tissue sarcoma, the investigators set up this project which aims to identify prognostic factors among geriatric and functional assessment.

Eligibility

Sex
ALL
Min age
70 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Aged more than 70 years, 2. Soft tissue sarcoma histologically proven, 3. Sarcoma of the soft tissues of the lower limbs, 4. Operable disease (first-line treatment or neo-adjuvant therapy), 5. ECOG, Performance Status ≤ 2, 6. Decision of surgery validated in Multidisciplinary Consultation Meeting, 7. Reports of the non-opposition documented in the patient file before any procedure specific to the study, 8. Affiliation to system of Social Security (accordance with article L1121-11 of the Code of Public Health). Exclusion Criteria: 1. Metastatic disease from the onset or relapse 2. Participation in another study involving a similar geriatric assessment. 3. Geographic, familial, social, psychological or psychiatric factors that make the patient incapable of undergoing the study's follow-up and procedures. 4. Persons deprived of liberty or placed under judicial protection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institut Bergonié Bordeaux France

More Institut Bergonié trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03077178 on ClinicalTrials.gov ↗ ← All trials in France